TW201613651A - Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative - Google Patents
Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivativeInfo
- Publication number
- TW201613651A TW201613651A TW104105731A TW104105731A TW201613651A TW 201613651 A TW201613651 A TW 201613651A TW 104105731 A TW104105731 A TW 104105731A TW 104105731 A TW104105731 A TW 104105731A TW 201613651 A TW201613651 A TW 201613651A
- Authority
- TW
- Taiwan
- Prior art keywords
- polymerized
- derivative
- drug
- pharmaceutical composition
- camptothecin derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/40—Polyamides containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014029049 | 2014-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201613651A true TW201613651A (en) | 2016-04-16 |
Family
ID=53878147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104105731A TW201613651A (en) | 2014-02-19 | 2015-02-17 | Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6461088B2 (ja) |
TW (1) | TW201613651A (ja) |
WO (1) | WO2015125641A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2995053A1 (en) * | 2015-09-03 | 2017-03-09 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition containing camptothecin polymer derivative |
EP3424513A4 (en) * | 2016-03-01 | 2019-10-23 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL PREPARATION WITH CAMPTOTHECINOUS POLYMER DERIVATIVE |
CN112279863A (zh) * | 2019-07-25 | 2021-01-29 | 华东师范大学 | Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1580216B1 (en) * | 2002-10-31 | 2014-05-14 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
US20090239782A1 (en) * | 2006-10-03 | 2009-09-24 | Masaharu Nakamura | High-molecular weight conjugate of resorcinol derivatives |
WO2013067162A1 (en) * | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
-
2015
- 2015-02-09 WO PCT/JP2015/053481 patent/WO2015125641A1/ja active Application Filing
- 2015-02-09 JP JP2016504039A patent/JP6461088B2/ja not_active Expired - Fee Related
- 2015-02-17 TW TW104105731A patent/TW201613651A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2015125641A1 (ja) | 2017-03-30 |
JP6461088B2 (ja) | 2019-01-30 |
WO2015125641A1 (ja) | 2015-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
MX2020012924A (es) | Terapias combinadas de coenzima q10 para el tratamiento de cancer. | |
NZ749218A (en) | Androgen receptor modulator and uses thereof | |
WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
MD4643C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
WO2013134407A3 (en) | Procaspase 3 activation by combination therapy | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
EP3162804A8 (en) | New benzodiazepine derivative and use thereof | |
NZ716765A (en) | Pharmaceutical combinations for the treatment of cancer | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
UA117581C2 (uk) | Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
MX2017015532A (es) | Terapia de combinacion pac-1. | |
MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
TW201613651A (en) | Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative | |
WO2016191703A3 (en) | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer | |
NZ712584A (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
WO2014115859A3 (ja) | 分子標的併用腫瘍治療・予防薬 |